EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry

Peter Bang, Michel Polak, Artur Bossowski iD, Mohamad Maghnie iD, Jesús Argente iD, Marta Ramon-Krauel iD, Caroline Sert, Valerie Perrot, Sarah Mazain, Joachim Woelfle iD

The Journal of Clinical Endocrinology & Metabolism · 21.12.2023 · 109 (1) · 46-56

DOI: 10.1210/clinem/dgad479 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 14.08.2023. Verfasst von Peter Bang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatrics, Department of Biomedical and Clinical Sciences, Faculty of Health Sciences, Linköping University, 581 83 Linköping, Sweden. Hauptthemen laut MEDLINE: Laron Syndrome, Hypoglycemia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ipsen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The European Increlex® Growth Forum Database (Eu-IGFD) is an ongoing surveillance registry (NCT00903110) established to collect long-term safety and effectiveness data on the use of recombinant human insulin-like growth factor-1 (rhIGF-1, mecasermin, Increlex) for the treatment of children/adolescents with severe primary insulin-like growth factor-1 deficiency (SPIGFD).

Objective

This analysis of Eu-IGFD data aimed to identify the frequency and predictive factors for hypoglycemia adverse events (AEs) in children treated with rhIGF-1.

Methods

Data were collected from December 2008 to May 2021. Logistic regression was performed to identify predictive risk factors for treatment-induced hypoglycemia AEs. Odds ratios (ORs) are presented with 95% CIs for each factor.

Results

In total, 306 patients were enrolled in the registry; 84.6% were diagnosed with SPIGFD. Patients who experienced ≥ 1 hypoglycemia AE (n = 80) compared with those with no hypoglycemia AEs (n = 224) had a lower mean age at treatment start (8.7 years vs 9.8 years), a more frequent diagnosis of Laron syndrome (27.5% vs 10.3%), and a history of hypoglycemia (18.8% vs 4.5%). Prior history of hypoglycemia (OR 0.25; 95% CI: [0.11; 0.61]; P = .002) and Laron syndrome diagnosis (OR 0.36; 95% CI: [0.18; 0.72]; P = .004) predicted future hypoglycemia AEs. Total hypoglycemia AEs per patient per treatment year was 0.11 and total serious hypoglycemia AEs per patient per treatment year was 0.01.

Conclusion

Hypoglycemia occurs more frequently in patients with prior history of hypoglycemia and/or Laron syndrome compared with patients without these risk factors, and these patients should be carefully monitored for this AE throughout treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Laron SyndromeHypoglycemiaChildAdolescentHumansLongitudinal StudiesInsulin-Like Growth Factor IRecombinant ProteinsDatabases, FactualLogistic Models

Stichwörter der Autor:innen

Eu-IGFD registryhypoglycemiamecaserminrhIGF-1severe primary insulin-like growth factor-1 deficiency

Substanzen

Insulin-Like Growth Factor IRecombinant Proteins

Autor:innen und Institutionen

  • Division of Pediatrics, Department of Biomedical and Clinical Sciences, Faculty of Health Sciences, Linköping University, 581 83 Linköping, Sweden.
  • Department of Pediatric Endocrinology, Gynaecology, and Diabetology, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Necker-Enfants Malades, 75015 Paris, France.
  • IMAGINE Institute, INSERM U1016, France University of Paris Cité, 75015 Paris, France.
  • Department of Pediatrics, Endocrinology, Diabetology with Cardiology Division, Medical University of Białystok, 15-274 Białystok, Poland.
  • Department of Pediatrics, IRCCS Istituto Giannina Gaslini, 16100 Genova, Italy.
  • Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health University of Genova, 16132 Genova, Italy.

ORCID-Profile: Artur Bossowski, Mohamad Maghnie, Jesús Argente, Marta Ramon-Krauel, Joachim Woelfle

Förderung

  • Ipsen

Zitieren

APA

Bang, P., Polak, M., Bossowski, A., Maghnie, M., Argente, J., Ramon-Krauel, M., Sert, C., Perrot, V., Mazain, S., & Woelfle, J. (2023). Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry. The Journal of Clinical Endocrinology & Metabolism, 109(1), 46-56. https://doi.org/10.1210/clinem/dgad479

Vancouver

Bang P, Polak M, Bossowski A, Maghnie M, Argente J, Ramon-Krauel M, et al. Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry. The Journal of Clinical Endocrinology & Metabolism. 2023;109(1):46-56. doi:10.1210/clinem/dgad479

BibTeX
@article{Bang2023,
  author = {Bang, Peter and Polak, Michel and Bossowski, Artur and Maghnie, Mohamad and Argente, Jesús and Ramon-Krauel, Marta and Sert, Caroline and Perrot, Valerie and Mazain, Sarah and Woelfle, Joachim},
  title = {Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {109},
  number = {1},
  pages = {46--56},
  doi = {10.1210/clinem/dgad479}
}
Kostenlos starten →